Zentek CEO Greg Fenton talks about bringing new antimicrobial HVAC filters to market
In this InvestorIntel interview with host Tracy Weslosky, Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton talks about new opportunities and commercial applications for their unique Zenguard antimicrobial coating.
In the interview, which can also be viewed in full on the InvestorIntel YouTube channel (click here), Greg tells Tracy “we’re focused quite acutely on the HVAC sector right now. We’re testing our unique antimicrobial coating on HVAC filters. Our Zenguard coating has been demonstrated to be effective against most airborne pathogens.” The interest in applying Zenguard to HVAC filters came out of a Canadian government call for new technologies to fight Covid-19, and Zentek won phase one of the challenges and is now onto phase two testing in real-world environments.
“If we’re successful,” Greg tells Tracy, “then the Government of Canada becomes an immediate client of ours and they will procure from us for a period of three years minimum.” He continues that the person in charge of the government testing facility “has told us that he has not seen anything even close to what we’ve been able to achieve so far, so we’re very excited about this and think we could have this product in the market later this year.”
To access the full InvestorIntel interview, click here
Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.
About Zentek Ltd.
Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have over 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.
To know more about Zentek Ltd., click here
Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.
This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.
This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.
Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.
If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].